ASPHALION experts Enrique Gutierrez and Marta Morales have participated this week in the 36-month follow-up and review meeting of the Horizon project Tumor-LN-oC in Athens to review the progress from the last 6 months.
Asphalion, in charge of the regulatory affairs, shared the results from the meeting carried out with the EMA Innovation Task Force (ITF) experts, where the regulatory strategy of the project was discussed, and presented the next steps planned in the project based on the recommendations from the meeting.
The EU-funded Tumor-LN-oC project proposes the development and validation of a TRL 5 tumor-lymph node-on-chip platform composed of 3D tissue models and microfluidic chips, which will connect surgically removed human primary tumors and LN tissue from the same lung cancer patients. This will serve as a “biological twin” of the patient and will allow to study the interaction of primary tumors with LNs for individual patients.
For a complete overview of the Tumor-LN-oC project, we invite you to have a look at the website: https://tumor-ln-oc.eu/
For additional information and for all your EU-funded project, you can also contact us at: horizon@asphalion.com
